
Opinion|Videos|January 31, 2025
Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS
Author(s)Thomas W. LeBlanc, MD, MA
Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of early and accurate diagnosis, considering newer therapies like luspatercept, monitoring hemoglobin levels, and incorporating patient-reported outcomes to tailor individualized treatment plans for better outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What clinical pearls could you share with community oncologists about the treatment of anemia for patients with LR-MDS?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































